Researchers evaluated population-based SEER data from 8,934 patients aged 70 or older with hormone receptor-positive T1-2N0M0 breast cancer to determine if adjuvant radiotherapy after breast-conserving surgery impacts survival.
Researchers analyzed data from women aged 70 and older diagnosed between 2016 and 2017 who underwent breast-conserving surgery, as detailed in a study published in the International Journal of Women’s Health.
Patient Survival Outcomes
The study used propensity score matching and inverse probability of treatment weighting to handle measured confounding across the large patient cohort. Among the 8,934 total patients, the analysis established 2,591 matched pairs to compare outcomes reliably.
At 60 months, overall survival reached 88.8 percent for patients who received radiotherapy compared to 82.3 percent for those who did not. Researchers connected radiation therapy to lower all-cause mortality with a hazard ratio of 0.572, alongside a reduced cause-specific hazard of breast cancer death at a cause-specific hazard ratio of 0.414.
The cumulative incidence of breast cancer death stood at 1.33 percent with radiotherapy versus 2.80 percent without it. Fine-Gray regression modeling produced a subdistribution hazard ratio of 0.442, reinforcing the observed survival differences in the matched cohort.
Expert Clinical Commentary
Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, said on LinkedIn that the findings provide “reason to be cautious about using age alone to recommend omission,” as reported by Oncodaily.
Mokbel said that administrative databases lack specific details regarding patient frailty, underlying comorbidities, and adherence to endocrine therapy. Healthier people may possess a higher likelihood of receiving radiation, and matching methods cannot fully resolve every unmeasured clinical difference between cohorts.
The PRIME II trial evaluated older women receiving endocrine therapy and found that at 10 years, local recurrence was 9.5 percent without radiotherapy versus 0.9 percent with it, while overall survival remained about 81 percent in both trial arms.